Search Results

• • 10,049 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Select 7C Viral infections

  1

  7C Viral infections

  From:Nurse Practitioners' Prescribing Reference (Vol. 21, Issue 2) Peer-Reviewed

  Summer 201416,504 words Drug overview 770LPRESCRIBING NOTES For more information on the management of HIV infection, see Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents--March 27, 2012 at www.aidsinfo.nih.gov....
• Select 7G Viral infections

  2

  7G Viral infections

  From:Nurse Practitioners' Prescribing Reference (Vol. 20, Issue 2) Peer-Reviewed

  Summer 201315,128 words Drug overview 770LPRESCRIBING NOTES For more information on the management of HIV infection, see Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents-March 27, 2012 at www.aidsinfo.nih.gov....
• Select 3F: Skin infections (topicals)

  3

  3F: Skin infections (topicals)

  From:Physician Assistants' Prescribing Reference (Vol. 20, Issue 2)

  Summer 20132,560 words Article 710LABREVA GlaxoSmithKline OTC Antiviral. Docosanol 10%; crm. Indications: Recurrent oral-facial herpes simplex episodes. Adults: Apply and gently rub in 5 times daily until healed. Begin treatment at earliest sign or...
• Select 3G skin infections (topicals)

  4

  3G skin infections (topicals)

  From:Nurse Practitioners' Prescribing Reference (Vol. 20, Issue 3) Peer-Reviewed

  Fall 20132,674 words Drug overview 710LABREVA GlaxoSmithKline OTC Antiviral. Docosanol 10%; crm. Indications: Recurrent oral-facial herpes simplex episodes. Adults: Apply and gently rub in 5 times daily until healed. Begin treatment at earliest sign or...
• Select 3F Skin infections (topicals)

  5

  3F Skin infections (topicals)

  From:Nurse Practitioners' Prescribing Reference (Vol. 20, Issue 2) Peer-Reviewed

  Summer 20132,572 words Drug overview 740LABREVA GlaxoSmithKline OTC Antiviral. Docosanol 10%; crm. Indications: Recurrent oral-facial herpes simplex episodes. Adults: Apply and gently rub in 5 times daily until healed. Begin treatment at earliest sign...
• Select 7C Viral infections

  6

  7C Viral infections

  From:Nurse Practitioners' Prescribing Reference (Vol. 21, Issue 3) Peer-Reviewed

  Fall 201416,666 words Drug overview 770LPRESCRIBING NOTES For more information on the management of HIV infection, see Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents--March 27, 2012 at www.aidsinfo.nih.gov....
• Select 3D Skin infections (topicals)

  7

  3D Skin infections (topicals)

  From:Nurse Practitioners' Prescribing Reference (Vol. 21, Issue 3) Peer-Reviewed

  Fall 20142,854 words Drug overview 700LABREVA GlaxoSmithKline OTC Antiviral. Docosanol 10%; crm. Indications: Recurrent oral-facial herpes simplex episodes. Adults: Apply and gently rub in 5 times daily until healed. Begin treatment at earliest sign...
• Select 7C Viral infections

  8

  7C Viral infections

  From:Nurse Practitioners' Prescribing Reference (Vol. 20, Issue 4) Peer-Reviewed

  Winter 201316,161 words Drug overview 770LPRESCRIBING NOTES For more information on the management of HIV infection, see Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents--March 27, 2012 at www.aidsinfo.nih.gov....
• Select 7C Viral infections

  9

  7C Viral infections

  From:Nurse Practitioners' Prescribing Reference (Vol. 23, Issue 1) Peer-Reviewed

  Spring 201619,255 words Drug overview 790LPRESCRIBING NOTES For more information on the management of HIV infection, see Guidelines for the Use of Antiretroviral Agents in HIV-1-lnfected Adults and Adolescents--March 27, 2012 atwww.aidsinfo.nih.gov....
• Select Zepatier

  10

  Zepatier

  From:Nurse Practitioners' Prescribing Reference (Vol. 23, Issue 2) Peer-Reviewed

  Summer 2016300 words Brief article, Drug ... 1380LCompany: Merck Rx Pharmacologic class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Active ingredients: Elbasvir, grazoprevir S0mg/1 OOmg; tablets. Indication: Chronic HCV genotypes 1 or 4 infection with...
• Select 3C Skin infections (topicals).

  11

  3C Skin infections (topicals).

  From:MPR - Physician Assistants' Edition (Vol. 23, Issue 2)

  Summer 20162,529 words Article 730L>ABREVA GlaxoSmithKline Rx Antiviral. Docosanol 10%; crm. Indications: Recurrent oral-facial herpes simplex episodes. Adults: Apply and gently rub in 5 times daily until healed. Begin treatment at earliest sign or...
• Select Technivie

  12

  Technivie

  From:Nurse Practitioners' Prescribing Reference (Vol. 22, Issue 4) Peer-Reviewed

  Winter 2015166 words Brief article 1210LCompany: AbbVie | Rx Pharmacologic class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor + CYP3A inhibitor Active ingredients: Ombi tasvir 12.5mg, paritaprevir 75mg, ritonavir 50mg; tablets. Indication: In...
• Select Sovaldi

  13

  Sovaldi

  From:Nurse Practitioners' Prescribing Reference (Vol. 21, Issue 1) Peer-Reviewed

  Spring 2014167 words Brief article 1190L Company: Gilead Sciences | Rx Pharmacologic class: Hepatitis C virus (HCV) NS5B polymerase inhibitor. Active ingredient: Sofosbuvir 400mg; tablets. Indication: As a component of a...
• Select Sitavig for herpes labialis

  14

  Sitavig for herpes labialis

  From:Nurse Practitioners' Prescribing Reference (Vol. 20, Issue 2) Peer-Reviewed

  Summer 201329 words Brief article 1190LSitavig (acyclovir), a nucleoside analog, has been approved for the treatment of recurring Herpes labialis. Sitavig will be available as a 50mg mucoadhesive tablet. For more information visit...
• Select Harvoni OK'd for more HCV patient populations

  15

  Harvoni OK'd for more HCV patient populations

  From:Nurse Practitioners' Prescribing Reference (Vol. 23, Issue 1) Peer-Reviewed

  Spring 2016101 words Brief article 1610LGilead Sciences announced that the FDA has approved Harvoni (ledipasvir/sofosbuvir) for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus (HCV) infection and in patients co-infected with HIV....
• Select Tyzeka

  16

  Tyzeka

  From:Physician Assistants' Prescribing Reference (Vol. 14, Issue 1)

  Spring 2007160 words Brief article 1460LCompanies: Idenix and Novartis Rx Pharmacologic class: Antiviral (nucleoside analogue reverse transcriptase inhibitor) Active ingredient: Telbivudine 600mg: tabs. Indication: Treatment of chronic hepatitis B in...
• Select 3D Skin infections (topicals)

  17

  3D Skin infections (topicals)

  From:Nurse Practitioners' Prescribing Reference (Vol. 21, Issue 2) Peer-Reviewed

  Summer 20142,763 words Drug overview 710LABREVA GlaxoSmithKline OTC Antiviral. Docosanol 10%; crm. Indications: Recurrent oral-facial herpes simplex episodes. Adults: Apply and gently rub in 5 times daily until healed. Begin treatment at earliest sign...
• Select Lower strength Kaletra

  18

  Lower strength Kaletra

  From:Physician Assistants' Prescribing Reference (Vol. 15, Issue 1)

  Spring 200841 words Brief article 1300LA lower-strength tablet formulation of Kaletra (lopinavir/ritonavir, from Abbott) has been approved for pediatric HIV patients. Kaletra 100mg/25mg tablets may be used in children weighing [greater than or equal to] 15kg...
• Select Ombitasvir/paritaprevir/ritonavir plus dasabuvir

  19

  Ombitasvir/paritaprevir/ritonavir plus dasabuvir

  From:Nurse Practitioners' Prescribing Reference (Vol. 23, Issue 1) Peer-Reviewed

  Spring 201636 words Brief article Ombitasvir/paritaprevir/ritonavir plus dasabuvir (Viekira Pak; Enanta and AbbVie) a combination antiviral regimen without ribavirin under review for an expanded indication to treat patients with genotype 1b (GT1b)...
• Select 7C Viral infections

  20

  7C Viral infections

  From:Nurse Practitioners' Prescribing Reference (Vol. 22, Issue 4) Peer-Reviewed

  Winter 201519,398 words Article 780LPRESCRIBING NOTES For more information on the management of HIV infection, see Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents--March 27, 2012 at www.aidsinfo.nih.gov. >...